ICON Public Limited Company

F:IJF Germany Diagnostics & Research
Market Cap
$6.66 Billion
€6.49 Billion EUR
Market Cap Rank
#2296 Global
#181 in Germany
Share Price
€85.02
Change (1 day)
+2.14%
52-Week Range
€72.94 - €170.30
All Time High
€314.40
About

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical stu… Read more

ICON Public Limited Company (IJF) - Net Assets

Latest net assets as of September 2025: €9.33 Billion EUR

Based on the latest financial reports, ICON Public Limited Company (IJF) has net assets worth €9.33 Billion EUR as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€16.51 Billion) and total liabilities (€7.17 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets €9.33 Billion
% of Total Assets 56.55%
Annual Growth Rate 33.48%
5-Year Change 414.69%
10-Year Change N/A
Growth Volatility 107.06

ICON Public Limited Company - Net Assets Trend (2016–2024)

This chart illustrates how ICON Public Limited Company's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for ICON Public Limited Company (2016–2024)

The table below shows the annual net assets of ICON Public Limited Company from 2016 to 2024.

Year Net Assets Change
2024-12-31 €9.52 Billion +3.05%
2023-12-31 €9.24 Billion +7.83%
2022-12-31 €8.57 Billion +6.24%
2021-12-31 €8.07 Billion +335.99%
2020-12-31 €1.85 Billion +14.35%
2019-12-31 €1.62 Billion +19.48%
2018-12-31 €1.35 Billion +13.71%
2017-12-31 €1.19 Billion +26.01%
2016-12-31 €945.17 Million --

Equity Component Analysis

This analysis shows how different components contribute to ICON Public Limited Company's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 363.5% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings €2.72 Billion 28.61%
Other Components €6.80 Billion 71.39%
Total Equity €9.52 Billion 100.00%

ICON Public Limited Company Competitors by Market Cap

The table below lists competitors of ICON Public Limited Company ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in ICON Public Limited Company's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 9,240,743,000 to 9,522,999,000, a change of 282,256,000 (3.1%).
  • Net income of 791,474,000 contributed positively to equity growth.
  • Share repurchases of 499,998,000 reduced equity.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income €791.47 Million +8.31%
Share Repurchases €500.00 Million -5.25%
Other Changes €-9.22 Million -0.1%
Total Change €- 3.05%

Book Value vs Market Value Analysis

This analysis compares ICON Public Limited Company's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.72x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 3.86x to 0.72x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 €22.02 €85.02 x
2018-12-31 €25.09 €85.02 x
2019-12-31 €30.18 €85.02 x
2020-12-31 €35.05 €85.02 x
2021-12-31 €98.91 €85.02 x
2022-12-31 €104.87 €85.02 x
2023-12-31 €112.02 €85.02 x
2024-12-31 €117.92 €85.02 x

Capital Efficiency Dashboard

This dashboard shows how efficiently ICON Public Limited Company utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 8.31%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 9.56%
  • • Asset Turnover: 0.49x
  • • Equity Multiplier: 1.77x
  • Recent ROE (8.31%) is below the historical average (15.45%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2016 27.74% 15.73% 0.91x 1.93x €167.66 Million
2017 23.63% 16.01% 0.82x 1.80x €162.39 Million
2018 23.82% 12.43% 1.10x 1.74x €187.23 Million
2019 23.11% 13.33% 0.97x 1.80x €212.18 Million
2020 17.96% 11.88% 0.81x 1.86x €147.31 Million
2021 1.90% 2.79% 0.32x 2.16x €-653.50 Million
2022 5.91% 6.55% 0.45x 2.01x €-350.71 Million
2023 6.63% 7.54% 0.48x 1.84x €-311.74 Million
2024 8.31% 9.56% 0.49x 1.77x €-160.83 Million

Industry Comparison

This section compares ICON Public Limited Company's net assets metrics with peer companies in the Diagnostics & Research industry.

Industry Context

  • Industry: Diagnostics & Research
  • Average net assets among peers: $12,070,206,496
  • Average return on equity (ROE) among peers: -40.71%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
ICON Public Limited Company (IJF) €9.33 Billion 27.74% 0.77x $6.58 Billion
Spermosens AB (publ) (9R5) $23.64 Million -27.17% 0.09x $517.28K
BML Inc (BMZ) $81.13 Billion 8.19% 0.43x $462.01 Million
Genomic Vision Société Anonyme (G09) $3.07 Million -162.85% 1.21x $711.54K
Adicon Holdings Limited (K0U) $1.77 Billion 2.65% 1.64x $138.53 Million
WuXi XDC Cayman Inc. (L74) $1.48 Billion 10.52% 0.69x $2.05 Billion
NanoRepro AG (NN6) $57.61 Million 51.59% 0.37x $17.02 Million
PERRIGO (PGO) $24.67 Million -167.93% 0.99x $6.37K